Kenneth Hoberman - 12 Jun 2025 Form 4 Insider Report for TG THERAPEUTICS, INC. (TGTX)

Reporting relationship
Director
Issuer ticker
TGTX
Reported as of
12 Jun 2025
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
16 Jun 2025, 17:46:18 UTC
Prior SEC filing
20 Jun 2024
Next SEC filing
15 Jun 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Kenneth Hoberman

Key filing fact

Kenneth Hoberman filed Form 4 for TG THERAPEUTICS, INC. (TGTX) on 16 Jun 2025.

Key facts

  • This page summarizes Kenneth Hoberman's Form 4 filing for TG THERAPEUTICS, INC. (TGTX).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 16 Jun 2025, 17:46.

Change

  • Previous filing in this sequence was filed on 20 Jun 2024.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001573722 Primary reporting owner

Hoberman Kenneth

Relationship
Director
Address
3020 CARRINGTON MILL BLVD, SUITE 475, MORRISVILLE
Signature
/s/ Kenneth Hoberman
Signature date
16 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TGTX transaction

Common Stock

Award

Transaction value
$0
Shares
+14,718
Change %
+5.6%
Price
$0.000000
Shares after
279,653
Date
12 Jun 2025
Ownership
Direct
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Reflects a grant of restricted shares that will vest on June 12, 2026.

Footnote F2

Includes shares of restricted Common Stock, which vest over various time periods.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .